Updated results from the ARIEL2 clinical trial of rucaparib in 152 patients with wild-type BRCA1/2 who were sensitive to platinum reported a response rate of 36% in those with BRCA-like DNA repair deficiency status. Here, BRCA1 is linked to hyperinsulinemic hypoglycemia, familial, 4.